Program
LTP001
A development code.
In Novartis's pipeline, SMURF1 inhibitor
. Its studies are mostly in Pulmonary Arterial Hypertension · Idiopathic Pulmonary Fibrosis, led by Novartis.
Furthest: phase 2, since Nov 16, 20213 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 30 open or running | phase 2since Nov 16, 2021 | Nov 16, 2021 | none ahead |
- Named in Novartis’s own pipeline as
LTP001
, phase 2, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 16, 2021First study: phase 2 study in Pulmonary Arterial HypertensionFirst studyNCT05135000 · 47 enrolled · United States, Argentina, Germany and more
- Aug 5, 2022Phase 2 study in Idiopathic Pulmonary FibrosisNCT05497284 · 46 enrolled · United States, Argentina, Australia and more
- Jan 10, 2023Phase 2 study in Pulmonary Arterial HypertensionNCT05764265 · 31 enrolled · United States, Argentina, Germany and more
TargetBeta
“SMURF1 inhibitor”the company's pipeline, read by Claude · source
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05764265Pulmonary Arterial Hypertension · United States, Argentina, Germany and more | 2 | Terminated | Apr 26, 2024 | 31 |
| NCT05497284Idiopathic Pulmonary Fibrosis · United States, Argentina, Australia and more | 2 | Terminated | Aug 26, 2024 | 46 |
| NCT05135000Pulmonary Arterial Hypertension · United States, Argentina, Germany and more | 2 | Terminated | Mar 20, 2024 | 47 |
How it is read
Names in the registry
- “LTP001”, 3 entries
Codes read as this program: LTP001.
Conditions, from the studies’ own filings
- Pulmonary Arterial Hypertension, 2 studies
- Idiopathic Pulmonary Fibrosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.